Article Text

This article has a correction. Please see:

Download PDFPDF
Weight loss induced by orlistat reverses fatty infiltration and improves hepatic fibrosis in obese patients with non-alcoholic steatohepatitis
  1. Nimer Assy,
  2. Osamah Hussein,
  3. Zied Abassi
  1. Department of physiology, Technion, Faculty of Medicine, Haifa, Israel
  1. Correspondence to:
    Dr N Assy
    Liver Unit, Sieff Government Hospital, POB 1008, Safed 13100, Israel; assy.n{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Non-alcoholic steatohepatitis (NASH) may cause progressive hepatic fibrosis and cirrhosis.1,2 To date, treatment has been restricted to diet and weight loss, but without compelling results. Orlistat (Xenical) is a natural lipase inhibitor, which reduces the absorption of dietary fat by 30%3 and improves insulin resistance and lipid profile.4,5 Whether or not orlistat reverses hepatic fibrosis and inflammation in obese patients with NASH has not been assessed.

A total of 14 obese patients with NASH underwent liver biopsy before and after 6 months treatment with orlistat (120 mg thrice daily). Patients were also provided a moderate calorie-restricted diet with a median daily intake of 25 kcal/kg body weight/day. Parameters of oxidative stress, insulin resistance, lipids and liver histology were measured. All patients signed informed consent. Of 22 recruited patients, 14 (10 women and 4 men, mean (SD) age of 42 (3) years, …

View Full Text


  • Competing interests: None declared.

Linked Articles

  • Corrections
    BMJ Publishing Group Ltd and British Society of Gastroenterology